LABS Stock Overview
A pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
MediPharm Labs Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.08 |
52 Week High | CA$0.10 |
52 Week Low | CA$0.055 |
Beta | 0.91 |
1 Month Change | 6.67% |
3 Month Change | 14.29% |
1 Year Change | 6.67% |
3 Year Change | -85.19% |
5 Year Change | -98.59% |
Change since IPO | -96.36% |
Recent News & Updates
Recent updates
Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost
Mar 23Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Jan 10MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?
Sep 06MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 17Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook
Aug 20Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates
May 21Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade
Apr 06Is MediPharm Labs (TSE:LABS) Using Too Much Debt?
Mar 07Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Aug 18Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates
May 23Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year
Jan 11Shareholder Returns
LABS | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | 6.7% | -5.6% | 0.3% |
1Y | 6.7% | 50.3% | 12.5% |
Return vs Industry: LABS underperformed the Canadian Pharmaceuticals industry which returned 50.3% over the past year.
Return vs Market: LABS underperformed the Canadian Market which returned 12.5% over the past year.
Price Volatility
LABS volatility | |
---|---|
LABS Average Weekly Movement | 16.4% |
Pharmaceuticals Industry Average Movement | 14.2% |
Market Average Movement | 8.9% |
10% most volatile stocks in CA Market | 17.9% |
10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: LABS has not had significant price volatility in the past 3 months.
Volatility Over Time: LABS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 166 | David Pidduck | www.medipharmlabs.com |
MediPharm Labs Corp., a pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products.
MediPharm Labs Corp. Fundamentals Summary
LABS fundamental statistics | |
---|---|
Market cap | CA$32.32m |
Earnings (TTM) | -CA$13.61m |
Revenue (TTM) | CA$36.99m |
0.9x
P/S Ratio-2.4x
P/E RatioIs LABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LABS income statement (TTM) | |
---|---|
Revenue | CA$36.99m |
Cost of Revenue | CA$26.63m |
Gross Profit | CA$10.36m |
Other Expenses | CA$23.97m |
Earnings | -CA$13.61m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.034 |
Gross Margin | 28.02% |
Net Profit Margin | -36.78% |
Debt/Equity Ratio | 4.2% |
How did LABS perform over the long term?
See historical performance and comparison